The Alexandria-based Ameriyah Pharmaceuticals company achieved a slight three percent net profit rise in the financial year 2001, reaching 69.2 million Egyptian pounds ($15 million), up from EP66.9 million in FY00.
The company’s bottom line growth was attributed to a seven percent increase in sales, which totaled EP191.2 million, compounded by a six percent rise in COGS (Cost of Goods Sold) reaching EP98.4 million. Gross profit thus totaled EP92.82 million, an eight percent rise over the previous year.
Founded in 1984, Ameriyah Pharmaceuticals produces and exports pharmaceuticals for human use and veterinary. The company’s shareholders include Rhone Poulenc, with an 18 percent stock, Arab Investors with 23 percent, Abd ElAziz Daghestany owning a 15 percent interest, CIIC with 16.5 percent, Synthelabo and Alexandria Maritime Bank with five percent each and the remaining 17.5 percent held by individual stockholders. — (menareport.com)
© 2002 Mena Report (www.menareport.com)
